Prevention of RSV Infections in Bone Marrow Transplant Recipients
Respiratory Syncytial Virus Infection
About this trial
This is an interventional treatment trial for Respiratory Syncytial Virus Infection focused on measuring Immunization, Immunocompromised, Immunoglobulin, Prophylaxis, Respiratory Virus, Bone Marrow Transplantation, Mini-Transplantation, Peripheral Stem Cell Transplantation
Eligibility Criteria
Male or female patients who are between the ages of 2 and 80 years. Must be admitted to the Bone Marrow Transplant Unit for a bone marrow transplantation (BMT), peripheral stem cell transplantation (PSCT) or mini-transplantation (MT). Must be in the early phase of BMT, PSCT or MT, i.e., receiving conditioning therapy for the transplant or within the first 30 days of receiving a bone marrow graft or; Must be greater than 30 days post-engraftment but being treated for Graft vs. Host disease (GVHD) with a total dose of equal to or greater than 1.5 grams/m(2) of methylprednisolone (or equivalent dose of steroids) over the first 3 days. Must have a negative result (at 48 hours) for RSV in the screening respiratory viral culture. Less than 8 days have elapsed between meeting eligibility criteria, being contacted by one of the investigators, and making a decision to join the study. Patients with signs or symptoms of Upper Respiratory Tract infection or pneumonia will be excluded until the etiology is established or RSV is ruled-out by the screening culture. Patients will be excluded if they have any condition that, in the opinion of the investigator, could affect their safety, preclude evaluation of response, or render unlikely that the contemplated course of therapy can be completed.
Sites / Locations
- National Institute of Allergy and Infectious Diseases (NIAID)